{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:57:31Z","timestamp":1783979851851,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijcrp.2025.200569","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:19:52Z","timestamp":1767629992000},"page":"200569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Davood","family":"Semirani-Nezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatere","family":"Roozbehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman Soltani","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Hashempoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Shamshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Azardar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshad","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani Khorsand","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Chichagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-3099","authenticated-orcid":false,"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: early detection should be focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci. Rep."},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib3","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200569_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection","volume":"13","author":"Long","year":"2011","journal-title":"J. Clin. Hypertens."},{"issue":"2_suppl","key":"10.1016\/j.ijcrp.2025.200569_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcrp.2025.200569_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12889-015-1999-4","article-title":"Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de Janeiro - brazil - 1991-2009","volume":"15","author":"da Silva","year":"2015","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.110.162446","article-title":"Cardiovascular outcomes in Framingham participants with diabetes","volume":"57","author":"Chen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcrp.2025.200569_bib8","first-page":"21","volume":"vol. 2","author":"Lindholm","year":"2000"},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200569_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.pcd.2023.09.007","article-title":"Associations of blood pressure with cardiovascular and mortality outcomes in over 2 million older persons with or without diabetes mellitus: a systematic review and meta-analysis of 45 cohort studies","volume":"17","author":"Seidu","year":"2023","journal-title":"Primary Care Diabetes"},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"38","key":"10.1016\/j.ijcrp.2025.200569_bib11","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ijcrp.2025.200569_bib12","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"issue":"Supplement_1","key":"10.1016\/j.ijcrp.2025.200569_bib13","first-page":"S6","article-title":"Summary of revisions: standards of care in Diabetes\u20142025","volume":"48","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcrp.2025.200569_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcte.2024.100335","article-title":"SGLT2 inhibitors: beyond glycemic control","volume":"35","author":"Hasan","year":"2024","journal-title":"Journal of Clinical & Translational Endocrinology"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib15","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13197","article-title":"Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling","volume":"29","author":"Chen","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"22","key":"10.1016\/j.ijcrp.2025.200569_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijcrp.2025.200569_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-017-0517-7","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data","volume":"16","author":"Davies","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib19","article-title":"Impact of SGLT2 inhibitors on preventing heart failure hospitalizations in Colombian patients with uncontrolled type 2 diabetes mellitus","volume":"17","author":"Vernaza Trujillo","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.ijcrp.2025.200569_bib20","doi-asserted-by":"crossref","DOI":"10.31661\/gmj.v14i.3604","article-title":"Circadian blood pressure as an indicator for cardiovascular complications: circadian blood pressure as an indicator for cardiovascular complications","volume":"14","author":"Al-Rikabi","year":"2025","journal-title":"Galen Medical Journal"},{"issue":"7","key":"10.1016\/j.ijcrp.2025.200569_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107590","article-title":"Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria \u2013 a double blind randomized placebo-controlled crossover trial","volume":"34","author":"Eickhoff","year":"2020","journal-title":"J. Diabetes Complicat."},{"issue":"18","key":"10.1016\/j.ijcrp.2025.200569_bib22","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in Black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijcrp.2025.200569_bib23","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","article-title":"Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"33","author":"Ferreira","year":"2020","journal-title":"Am. J. Hypertens."},{"issue":"8","key":"10.1016\/j.ijcrp.2025.200569_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib26","article-title":"Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms","volume":"12","author":"Cheng","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200569_bib27","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sj\u00f6str\u00f6m","year":"2015","journal-title":"Diabetes Vasc. Dis. Res."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-Hour ambulatory blood pressure after 6-Week treatment with Canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J. Clin. Hypertens."},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"10.1016\/j.ijcrp.2025.200569_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of Canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J. Clin. Hypertens."},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200569_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.eprac.2024.03.001","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on the 24-Hour ambulatory blood pressure in patients with type 2 diabetes mellitus and hypertension: an updated meta-analysis","volume":"30","author":"Iqbal","year":"2024","journal-title":"Endocr. Pract."},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200569_bib33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfab048","article-title":"Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"37","author":"Tian","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ijcrp.2025.200569_bib34","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcrp.2025.200569_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone System","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.ijcrp.2025.200569_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ehjcvp\/pvad053","article-title":"The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10.1016\/j.ijcrp.2025.200569_bib37","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200569_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5543\/tkda.2022.22403","article-title":"Impact of sodium-glucose Cotransporter-2 inhibitors on sympathetic nervous System activity detected by sympathetic activity index and LF\/HF ratio in patients with type 2 diabetes mellitus","volume":"50","author":"Balc\u0131o\u011flu","year":"2022","journal-title":"Turk Kardiyol. Dernegi Arsivi"},{"issue":"9","key":"10.1016\/j.ijcrp.2025.200569_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.ijcrp.2025.200569_bib41","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/dom.14729","article-title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: results from DAPASALT and DIAMOND","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.ijcrp.2025.200569_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose Co-Transporter 2 inhibitor, Dapagliflozin, on renal renin-angiotensin System in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200569_bib45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: Dose-Response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200569_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/hr.2016.2","article-title":"A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats","volume":"39","author":"Takeshige","year":"2016","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200569_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7888\/juoeh.38.149","article-title":"A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by Dapagliflozin","volume":"38","author":"Mori","year":"2016","journal-title":"J. UOEH"},{"issue":"9","key":"10.1016\/j.ijcrp.2025.200569_bib48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1291\/hypres.26.669","article-title":"Role of insulin resistance in nondipper essential hypertensive patients","volume":"26","author":"Anan","year":"2003","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200569_bib49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"22","key":"10.1016\/j.ijcrp.2025.200569_bib50","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9733","key":"10.1016\/j.ijcrp.2025.200569_bib51","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jch.12026","article-title":"Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension","volume":"15","author":"Turak","year":"2013","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcrp.2025.200569_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/5553327","article-title":"Efficacy and safety of ertugliflozin compared to placebo in patients with type 2 diabetes: an updated systematic review and meta-analysis","volume":"2024","author":"Kamrul-Hasan","year":"2024","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200569_bib54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12902-024-01805-z","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"24","author":"Teng","year":"2024","journal-title":"BMC Endocr. Disord."},{"issue":"21","key":"10.1016\/j.ijcrp.2025.200569_bib55","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200569_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001856","article-title":"Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study","volume":"8","author":"Horii","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200569_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial combination therapy with Canagliflozin plus metformin versus each component as monotherapy for Drug-Na\u00efve type 2 diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcrp.2025.200569_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1256548","article-title":"Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200569_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/medicina61020202","article-title":"Update on the efficacy and safety of sodium\u2013glucose Co-Transporter 2 inhibitors in patients with chronic diseases: a systematic review and meta-analysis","volume":"61","author":"Liang","year":"2025","journal-title":"Medicina"},{"key":"10.1016\/j.ijcrp.2025.200569_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200569_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088687","article-title":"Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis","volume":"15","author":"Xu","year":"2025","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.ijcrp.2025.200569_bib62","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s12325-024-02879-w","article-title":"Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials","volume":"41","author":"Wanner","year":"2024","journal-title":"Adv. Ther."},{"issue":"14","key":"10.1016\/j.ijcrp.2025.200569_bib63","first-page":"1318","article-title":"SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension","volume":"46","author":"Messerli","year":"2025","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487525002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487525002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:27:11Z","timestamp":1783603631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772487525002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"alternative-id":["S2772487525002077"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200569","relation":{},"ISSN":["2772-4875"],"issn-type":[{"value":"2772-4875","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200569"}}